XORTX Income Tax Expense from 2010 to 2025

XRTX Stock  USD 0.92  0.09  10.84%   
XORTX Therapeutics Income Tax Expense yearly trend continues to be fairly stable with very little volatility. Income Tax Expense is likely to outpace its year average in 2025. During the period from 2010 to 2025, XORTX Therapeutics Income Tax Expense regression line of annual values had r-squared of  0.06 and arithmetic mean of  9,242. View All Fundamentals
 
Income Tax Expense  
First Reported
2017-03-31
Previous Quarter
1.9 M
Current Value
1
Quarterly Volatility
1.2 M
 
Covid
Check XORTX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XORTX Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 996.5 K, Other Operating Expenses of 5.8 M or Total Operating Expenses of 5.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.88. XORTX financial statements analysis is a perfect complement when working with XORTX Therapeutics Valuation or Volatility modules.
  
Check out the analysis of XORTX Therapeutics Correlation against competitors.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

Latest XORTX Therapeutics' Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of XORTX Therapeutics over the last few years. It is XORTX Therapeutics' Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in XORTX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Pretty Stable
   Income Tax Expense   
       Timeline  

XORTX Income Tax Expense Regression Statistics

Arithmetic Mean9,242
Geometric Mean0.00
Coefficient Of Variation102.25
Mean Deviation5,768
Median8,625
Standard Deviation9,451
Sample Variance89.3M
Range37.2K
R-Value(0.24)
Mean Square Error90.3M
R-Squared0.06
Significance0.37
Slope(472.40)
Total Sum of Squares1.3B

XORTX Income Tax Expense History

2025 -0.00855
2024 -0.009
2023 -0.01
2022null
2021 4390.52
202013.5 K
201937.2 K

About XORTX Therapeutics Financial Statements

XORTX Therapeutics investors use historical fundamental indicators, such as XORTX Therapeutics' Income Tax Expense, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in XORTX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Tax Expense(0.01)(0.01)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.